Start with the registry, then confirm with the study team

The TED search on ClinicalTrials.gov links to study records. Read the purpose, study status, eligibility description, locations, sponsor, and contact information. Check the record’s update date. Information can lag, so a listing is not confirmation that a site is currently enrolling.

Study sponsors or investigators provide the registry information. ClinicalTrials.gov does not establish that every listed study has been evaluated by the U.S. government. Save the study identifier and record link so your clinician and the research team can discuss the same study.

Evidence: ClinicalTrials.gov: registry and limits of listed study information · ClinicalTrials.gov: common questions for patients

Eligibility is assessed by the research team

A description may mention disease features, earlier treatments, other health conditions, or timing requirements. Reading it can help you prepare questions, but it cannot confirm eligibility. The study team must apply the protocol and explain the screening process.

Ask whether the specific location is recruiting now and what screening involves. Before sharing records, confirm the team’s official contact and ask for its secure process. This educational site does not accept applications, medical records, member identifiers, or trial screening information.

Evidence: ClinicalTrials.gov: common questions for patients

Questions to take to the research conversation

What question is the study trying to answer, and what is experimental?
What are the possible benefits, known risks, uncertainties, and alternatives?
Could I receive a placebo or a different treatment, and how is assignment decided?
Which visits, tests, travel, and time away from work would be involved?
Which costs are covered by the study, which may be billed to insurance, and which could be mine?
Who do I contact about side effects, urgent care, privacy, or questions?
What happens if I choose not to join or decide to stop participating?
What care and follow-up are available after participation ends?

Evidence: NIH Clinical Center: why participate in a clinical trial? Questions to ask · FDA: informed consent guidance for IRBs, clinical investigators and sponsors

Consent is a discussion you should understand

Read the consent information and ask for time to discuss it. The conversation should explain the research, procedures, foreseeable risks, possible benefits, alternatives, contacts, and relevant costs. An opportunity to ask questions matters as much as receiving a form. Participation is voluntary.

Ask the team to separate research procedures from ordinary clinical care and explain which responsibilities belong to each team. If you are unsure about an answer, request clarification before deciding. Do not assume that access to an investigational treatment is the same as proven benefit.

Evidence: FDA: informed consent guidance for IRBs, clinical investigators and sponsors

Keep your ordinary care plan clear

Tell your eye specialist about any study you are considering and ask how it would affect current treatment and follow-up. Do not stop prescribed care or delay urgent eye assessment while exploring research. The practical goal is an informed decision, including the option not to participate.

Use the visit planner to keep the study identifier, your questions, and the next conversation together. This guide contains no live recruiting-study count and makes no claim that a particular study or place is available today.

Evidence: NIH Clinical Center: why participate in a clinical trial? Questions to ask

Sources and limits

Sources checked October 22, 2026. This is an original educational summary. Source dates and access notes are distinct from clinical review. A clinical professional should review this new material before it is promoted as reviewed.